View More Recent Stories
-
TD Cowen: '10 Potential "Thome Run" Catalysts to Watch in 2025'
-
United Therapeutics (UTHR) Announces Successful World’s First UKidney Transplant
-
United Therapeutics Corp. (UTHR) PT Raised to $344 at Ladenburg Thalmann
-
United Therapeutics Corp. (UTHR) PT Raised to $425 at H.C. Wainwright
-
United Therapeutics (UTHR) Misses Q3 EPS by 14c
-
LifeSci Capital Reiterates Outperform Rating on Liquidia Technologies (LQDA)
-
United Therapeutics Corp. (UTHR) PT Raised to $432 at Jefferies
-
United Therapeutics Corp. (UTHR) PT Raised to $575 at Oppenheimer
-
United Therapeutics Corp. (UTHR) PT Raised to $380 at Wells Fargo
-
Goldman Sachs Reiterates Neutral Rating on United Therapeutics Corp. (UTHR)
-
TD Cowen Reiterates Buy Rating on United Therapeutics Corp. (UTHR)
-
United Therapeutics (UTHR) Misses Q2 EPS by 63c
-
United Therapeutics Corp. (UTHR) PT Raised to $400 at H.C. Wainwright
-
United Therapeutics Corp. (UTHR) PT Raised to $350 at TD Cowen
-
Morgan Stanley Downgrades United Therapeutics Corp. (UTHR) to Equalweight
-
United Therapeutics Corp. (UTHR) PT Raised to $350 at Argus
-
United Therapeutics Corp. (UTHR) PT Raised to $370 at UBS
-
United Therapeutics (UTHR) Appoints Jan Malcolm to its Board
-
United Therapeutics Corp. (UTHR) PT Lowered to $262 at BofA Securities
-
Grow your wealth: UBS reveals top long-term stock picks
-
Martine Rothblatt is Featured in Forbes Magazine's Special Centennial Issue as one of The World's 100 Greatest Living Business Minds

